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Abstract
Background: The natural history of non-metastatic castrate refractory prostate cancer is unknown and treatment
options are limited. We present a retrospective review of 13 patients with locally advanced or high risk prostate
cancer, initially treated with hormone monotherapy and then treated with prostate radiation after becoming
castration refractory.
Findings: Median PSA response following prostate radiation was 67.4%. Median time to biochemical progression
following radiotherapy was 15 months and to detection of metastatic disease was 18.5 months. Median survival
from castration resistance (to date of death or November 2011) was 60 months, with median survival from RT 42
months.
Conclusion: Prostate radiation appears to be beneficial even in patients with potential micrometastatic disease,
which supports the hypothesis that the primary tumour is important in the progression of prostate cancer. These
results are an interesting addition to the literature on the biology of prostate cancer especially as this data is
unlikely to be available in the future due to combined prostate radiation and androgen deprivation therapy now
being the standard of care.
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Introduction
The combination of androgen deprivation therapy and
prostate radiation (RT) is currently the standard of care
for high risk and locally advanced prostate cancer
patients. But prior to the publication of MRC PR07 and
the SPCG-7/SFUO-3 trial results showing a survival
benefit from adding radical radiotherapy to androgen
deprivation therapy [1,2], primary hormone monother-
apy was a treatment option for selected cases of locally
advanced and high risk prostate cancer [3,4]. Adding
prostate radiation for these patients when they become
castration refractory (and still have radiologically loca-
lised cancer) is controversial, but there is some evidence
that patients with locally advanced, castration refractory
prostate cancer (CRPC) may benefit from prostate radia-
tion [5].
T h en a t u r a lh i s t o r yo fn o n - m e t a s t a t i cC R P Ci s
unknown, and treatment options are limited. Metastatic
CRPC is associated with poor prognosis; average survival
being 12-18 months, which with PSA lead time may be
an underestimate [6].
Patients
We undertook a retrospective review of 13 patients from
follow up clinics who received RT for localised CRPC.
All 13 patients received their first hormone treatment
between 1996 and 2005 under the urology team and
were referred for oncology opinion after castration resis-
tance; the majority of patients were started on 2
nd line
or even 3
rd line hormones prior to referral to the oncol-
ogy team and then required staging investigations,
hence the delay between castration resistant state and
start of radiotherapy. At the time of diagnosis, 5 patients
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to their high PSA level, 2 patients were given the choice
of radiotherapy but chose hormone monotherapy, one
patient was having chemotherapy for lymphoma and for
the other 5 patients the reasons for choice of hormone
monotherapy was unclear; inadequate documentation
being one of the constraints of a retrospective review.
10 patients received LHRH agonist therapy as primary
hormone treatment, 2 received diethylstilboestrol and 1
patient had surgical castration. Our institution also
recruited patients to the MRC PR07 trial comparing pri-
mary hormone monotherapy vs hormones plus RT com-
bination therapy and these patients were treated outside
that trial. Prior to radical RT all patients had imaging to
exclude metastatic disease, 61% of patients had CT
body, 85% had bone scan and 46% had both.
Castration refractory state was defined as first
increase in PSA of 2 above nadir; median (range) time
to castration refractory state was 44 months (14-140).
The characteristics of prostate cancer at diagnosis
w e r e :G l e a s o ns c o r e :5=1 ;6=4 ;7=5 ;9=1 ;n o
information was available for 2 patients; T1 = 1; T2 =
7; T3 = 3, T4 = 1; no T stage was available for 1
patient. Median (range) PSA at diagnosis was 51.85
(19-593). Patients received prostate radiation with a
median dose of 64Gy (range 60-70) in 32# (30-38).
Median (range) age at time of diagnosis was 63 (54-77)
and at start of RT was 73 (64-81) and median (range)
PSA prior to RT was 16(2.1-163). All patients contin-
ued with LHRH agonists during and after radiotherapy;
46% of patients had concurrent maximal androgen
blockade with bicalutamide during and after radiother-
apy, 31% had concurrent prednisolone and 1 patient
had ketoconazole and hydrocrotisone, while 1 patient
had LHRH agonist alone. Following biochemical
relapse, patients were treated with further hormone
manipulation; 6 patients received chemotherapy with
docetaxel following diagnosis of metastatic disease.
Results
Median PSA response was 67.4% (range 0-99.5%). Bio-
chemical progression following RT was defined as first
increase in PSA of 2 above post-RT nadir; median time
after RT to biochemical progression was 15 (range 0-49)
months, and to detection of metastatic disease was 18.5
(range 4-67) months. Median survival from castration
resistance (to date of death or November 2011) was 60
(range 49-106) months, with median survival from RT
42 (range 23-77) months, only 4 of the 13 patients have
died so further follow up may show improved survival
data. There was no clinical local failure.
SPSS18 statistics software was used to calculate Spear-
m a n sr a n kc o r r e l a t i o na n ds h o w e dt h a tP S Ap r e - r a d i o -
therapy was negatively correlated with times to
progression and development of metastatic disease (time
to progression r = -0.669, p = 0.017; time to metastases,
r = -0.667, p = 0.025). Percentage PSA response was
positively correlated with both time to progression and
time to metastatic disease (time to progression r =
0.813, p = 0.001; time to metastases r = 0.717, p =
0.013). PSA is therefore likely to be a useful marker of
outcome in CRPC treated with RT; although neither of
the correlations remained significant with overall survi-
val, this may be due to the fact 9 patients in the series
are still alive.
Conclusion
With the caveats associated with a retrospective study,
we conclude that prostate radiation has a clinical benefit
for this sub group of patients. The benefits of prostate
radiation in patients with localised CRPC are twofold:
for local control of cancer, to prevent distressing local
symptoms and to delay eventual overall disease progres-
sion. Clinically in this series there were no events of
local failure although post-radiation prostate biopsy was
not done to confirm this; radiotherapy was well toler-
ated with no episodes of grade 3 or 4 toxicity. In terms
of distant failure, we hypothesise that prostate ‘resident’
stem cells may influence the natural history of prostate
cancer even in the presence of micrometastases. A large
retrospective study by Oefelein et al [6] reported that
the median survival after the development of hormone-
refractory disease was 40 months in the subgroup of
patients with evidence of skeletal metastasis at diagnosis
and 68 months in the subgroup without skeletal metas-
tasis. The survival of patients in our series is comparable
to that reported by Oefelein and thereby rules out sig-
nificant selection bias inherent with a retrospective
study; of note, patients in that study were taken to have
CRPC from the time of PSA rise above 0.3, whereas our
study used the RTOG-ASTRO definition of CRPC (PSA
of 2 + nadir) [7], suggesting a lead time on their survival
data when compared to our series.
These results show that prostate radiation may be
beneficial even in the presence of potential micro metas-
tases in these high risk patients, suggesting that the pri-
mary tumour may be a factor in promoting progression.
This case series therefore provides support for the
hypothesis that potential prostate cancer stem cells
within the prostate play a part in the evolution of the
disease in the presence of micrometastases [8]; thus also
providing indirect support to the proposed EORTC trial
exploring the role of prostate radiotherapy in patients
with newly diagnosed metastatic prostate cancer (Pro-
posed EORTC trial: SELECTION: Systemic and local
therapy for newly diagnosed M1 prostate cancer: investi-
gating the role of up-front cabazitaxel and irradiation of
the prostate).
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the literature on the biology of prostate cancer, as com-
bined prostate irradiation and androgen deprivation
therapy is now standard care, and therefore it is very
unlikely that this information on the natural history of
prostate cancer will be available in the future.
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